Article Impact Level: HIGH Data Quality: STRONG Summary of European Heart Journal, ehac401. https://doi.org/10.1093/eurheartj/ehac401 Dr. Javed Butler et al
Points
- The goal of this trial was to evaluate the role of patiromer as compared to control in patients with heart failure with reduced ejection fraction (HFrEF) as well as a history of hyperkalemia.
- The result of the trial indicated that patiromer was effective for maintaining a lower level of serum potassium in patients with HFrEF.
- The results of this trial indicated that patiromer is beneficial for patients having HFrEF and a history of hyperkalemia.
- Patiromer is also associated with controlling the incidence of hyperkalemia as compared to control.
Summary
To explore the effectiveness of patiromer for patients with HFrEF, a DIMOND trial was carried out. In this trial, 878 patients were selected for a follow-up of 13 weeks. Patients were randomized into two groups: patiromer (n=439) and control (n=439). Before the randomization run-in phase was started in which, all patients had patiromer; after that, they were grouped in stop patiromer and continue patiromer groups. For this trial, patients having HFrEF with New York Heart Association class II-IV symptoms, having beta-blocker, or those who were unable to tolerate beta blockers and currently having hyperkalemia or it history were included. Patients with acute heart failure, glomerular filtration rate less than 30ml/min, systolic BP less than 90 mmHg, or major cardiovascular disease within the last 4 weeks were not included.
The results of this trial indicated that patiromer is beneficial for patients having HFrEF and a history of hyperkalemia. Patiromer helps to maintain the lower level of serum potassium and is also associated with controlling the incidence of hyperkalemia as compared to control.
Link to the article: https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehac401/6651164
References Butler, J., Anker, S. D., Lund, L. H., Coats, A. J. S., Filippatos, G., Siddiqi, T. J., Friede, T., Fabien, V., Kosiborod, M., Metra, M., Piña, I. L., Pinto, F., Rossignol, P., van der Meer, P., Bahit, C., Belohlavek, J., Böhm, M., Brugts, J. J., Cleland, J. G. F., … Pitt, B. (2022). Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: The DIAMOND trial. European Heart Journal, ehac401. https://doi.org/10.1093/eurheartj/ehac401
